Literature DB >> 6821202

Antibody response to Pseudomonas aeruginosa exoproducts in cancer patients.

K E Crowe, J A Bass, V M Young, D C Straus.   

Abstract

We analyzed sera from 28 patients with various types of malignancies for the occurrence of antibodies against exotoxin A of Pseudomonas aeruginosa and two Pseudomonas proteases. A total of 27 of these individuals were colonized or infected with P. aeruginosa at one time or another during the study, whereas the remaining patient was colonized with four non-P. aeruginosa species of Pseudomonas. Sera were obtained from several of these patients before P. aeruginosa colonization or infection of these individuals was detected, which provided an opportunity to evaluate their responsiveness to pseudomonal exoproducts as they acquired the organism. Exotoxin A was purified from culture supernatant fluids of strain PA-103, and the two proteases were purified from an isolate of strain JR3, a highly proteolytic strain originally recovered from the sputum of a cystic fibrosis patient. Antibodies to the exotoxin A and the two proteases were detected in these sera, and sera which contained relatively high antibody levels to exotoxin A afforded mice complete protection against lethal challenges with this substance. Statistical analyses showed that patients infected with P. aeruginosa had consistently higher antibody levels (P less than 0.005) to the exoproducts than patients who were colonized with this organism. Also, patients colonized with P. aeruginosa possessed significantly higher antibody levels (P less than 0.003) to these three exoproducts than uninfected, hospitalized patients. Parke-Davis type 1 was the strain most commonly isolated from these patients (46%), but colonization or infection due to this organism usually resulted in the production of low levels of antibody to Pseudomonas exoproducts. However, infections with Parke-David type 7 organisms were always associated with intermediate- and high-responder sera to exotoxin A. These results indicated that potentially toxic products were elaborated during the course of cancer-related colonization and infection with P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6821202      PMCID: PMC272035          DOI: 10.1128/jcm.15.1.115-122.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  21 in total

1.  NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.

Authors:  B H Iglewski; D Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

2.  Pseudomonas bacteremia in patients with malignant diseases.

Authors:  J P Whitecar; M Luna; G P Bodey
Journal:  Am J Med Sci       Date:  1970-10       Impact factor: 2.378

3.  Characteristics of nonbacteremic Pseudomonas pneumonia.

Authors:  J R Tillotson; A M Lerner
Journal:  Ann Intern Med       Date:  1968-02       Impact factor: 25.391

4.  Epidemiological studies of Pseudomonas species in patients with leukemia.

Authors:  G P Bodey
Journal:  Am J Med Sci       Date:  1970-08       Impact factor: 2.378

5.  Pseudomonas pneumonia: a prototype of hospital-based infection.

Authors:  R R Renner; A P Coccaro; E R Heitzman; E T Dailey; B Markarian
Journal:  Radiology       Date:  1972-12       Impact factor: 11.105

6.  Serogroups of Pseudomonas aeruginosa and the immune response of patients with cystic fibrosis.

Authors:  E Diaz; L L Mosovich; E Neter
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

7.  Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa.

Authors:  S H Leppla
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

8.  Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.

Authors:  M Pollack; L T Callahan; N S Taylor
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

9.  Serotyping of Pseudomonas aeruginosa isolates from patients with cystic fibrosis of the pancreas.

Authors:  C H Zierdt; R L Williams
Journal:  J Clin Microbiol       Date:  1975-06       Impact factor: 5.948

10.  INTRACELLULAR HEMOLYSIN OF PSEUDOMONAS AERUGINOSA.

Authors:  R S BERK
Journal:  J Bacteriol       Date:  1963-03       Impact factor: 3.490

View more
  9 in total

1.  MexT regulates the type III secretion system through MexS and PtrC in Pseudomonas aeruginosa.

Authors:  Yongxin Jin; Hongjiang Yang; Mingqiang Qiao; Shouguang Jin
Journal:  J Bacteriol       Date:  2010-11-12       Impact factor: 3.490

2.  Prevalence of protease and elastase production by clinical isolates of Pseudomonas aeruginosa in relation to aeruginocine typing patterns.

Authors:  R Kapur
Journal:  Eur J Epidemiol       Date:  1986-09       Impact factor: 8.082

3.  Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

4.  Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis.

Authors:  J S Lam; L M Mutharia; R E Hancock; N Høiby; K Lam; L Baek; J W Costerton
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

5.  Evaluation of three serological tests for detection of antibody to Pseudomonas aeruginosa in human sera.

Authors:  T L Pitt; H C Todd; C A Mackintosh; S W Im
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

6.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.609

7.  Trafficking of Pseudomonas exotoxin A in mammalian cells.

Authors:  C B Saelinger; R E Morris; G Foertsch
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 5.103

8.  Enzyme-linked immunosorbent assay for detection of antibodies to Pseudomonas aeruginosa exoproteins.

Authors:  M Granström; B Wretlind; B Markman; O R Pavlovskis; M L Vasil
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 5.103

9.  Comparative analysis of serum antibody responses to Pseudomonas aeruginosa exotoxin A by cystic fibrosis and intensive care unit patients.

Authors:  G Cukor; N R Blacklow; N A Nowak; C M Rich; L E Braverman; R A Fischer
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 11.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.